

DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I (we) hereby declare that:

My (our) residence(s), post office address(es) and citizenship(s) is (are) the same as stated below next to my (our) name(s).

I (we) believe I am (we are) an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR TARGETING

the specification of which is attached hereto unless the following box is checked:

☒ was filed on March 28, 2001 as United States Application Number 09/819,266
and was amended on _____ (if applicable).

I (we) hereby state that I (we) have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I (we) acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I (we) hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):			Priority Claimed:	
(Number)	(Country)	(Day/Month/Year)	YES	NO
0007343.7	United Kingdom	28/3/2000	X	

I (we) hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

60/193,156 March 28, 2000
(Application Number) (Filing Date)

I (we) hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I (we) acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulation, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Serial No.)	(Filing date)	(STATUS-patented, pending, abandoned)

I (we) hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Lloyd McAulay, Reg. No. 20,423; J. Harold Nissen, Reg. No. 17,283; Jules E. Goldberg, Reg. No. 24,408;
Gerald H. Kiel, Reg. No. 25,116; Eugene LeDonne, Reg. No. 35,930; Stephen M. Chin, Reg. No. 39,938;
Arthur Dresner, Reg. No. 24,403; Samir R. Patel, Reg. No. 44,998; Daniel P. Lent, Reg. No. 44,867;

all of Reed Smith LLP, 375 Park Avenue, New York, New York 10152.

Address all telephone calls to: Jules E. Goldberg, Esq. at Telephone No. (212) 986-4090

Address all correspondence to: Jules E. Goldberg, Esq.
Reed Smith LLP
375 Park Avenue, New York, NY 10152 U.S.A.

I (we) hereby declare that all statements made herein of my (our) own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or 1st inventor (given name, family name): Agamemnon Antoniou EPENETOS

Residence:	Flat 1, 6 Upper Park Road London NW3 2UP, United Kingdom	Citizenship:	United Kingdom
Post Office Address:	ICRF Oncology Group, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, DuCane Road, London WC12 OHS United Kingdom		

Inventor's signature: 

Date: 15/10/01

Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

H8

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE